Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.

"Declarations Ethics approvalBiomaterial samples were provided by the RWTH centralized Biomaterial Bank Aachen (RWTH cBMB, Aachen, Germany) in accordance with the regulations of the biomaterial bank and the approval of the ethics committee (EK 127/12) of the medical faculty, RWTH Aachen. Consent to participateSee “Ethics approval.” Consent for publicationThe patients’ written informed consent includes a statement that their data will be published. Competing interestsS. K. reports funding from Novartis, Bristol-Myers Squibb, and Janssen/Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, and Sanofi; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, and AOP Pharma; and other financial support (e.g., travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, and Karthos. T. H. B. served as a consultant for Janssen, Merck, Novartis, and Pfizer; received research funding from Novartis and Pfizer; and received honorarium from Pfizer. D. G. reports advisory board honoraria from AMGEN, Celgene, TAKEDA, and Janssen; served as Invited Speaker for AMGEN, Celgene, BMS, and TAKEDA; and received other financial support (e.g., travel support) from TAKEDA, Celgene, and AMGEN. S. I. reports honoraria and membership on entity’s Board of Directors or advisory committees from Ariad, Novartis, and Pfizer as well as honoraria from BMS and travel reimbursement from Alexion, Amgen, Hexal, Mundipharma, Pfizer, Roche, and Novartis. Competing interests S. K. reports funding from Novartis, Bristol-Myers Squibb, and Janssen/Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, and Sanofi; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, and AOP Pharma; and other financial support (e.g., travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, and Karthos. T. H. B. served as a consultant for Janssen, Merck, Novartis, and Pfizer; received research funding from Novartis and Pfizer; and received honorarium from Pfizer. D. G. reports advisory board honoraria from AMGEN, Celgene, TAKEDA, and Janssen; served as Invited Speaker for AMGEN, Celgene, BMS, and TAKEDA; and received other financial support (e.g., travel support) from TAKEDA, Celgene, and AMGEN. S. I. reports honoraria and membership on entity’s Board of Directors or advisory committees from Ariad, Novartis, and Pfizer as well as honoraria from BMS and travel reimbursement from Alexion, Amgen, Hexal, Mundipharma, Pfizer, Roche, and Novartis."

"Funding Open Access funding enabled and organized by Projekt DEAL. This work was in part funded by grants to S. K. from Novartis (HINC-212) and the Deutsche Forschungsgemeinschaft (German Research Foundation) (DFG KO 2155/6-1, AOBJ 636363)."